Table 4. Comparison of AKI and non-AKI patients treated with AS colistin.
| AKI (n = 12) |
Non-AKI (n = 141) |
p-valuea | |
|---|---|---|---|
| Duration of colistin use (day) | 18.83 (8.31) | 12.09 (9.76) | 0.022 |
| Baseline SCr (mg/dL) | 2.10 (2.11) | 0.74 (0.59) | 0.047 |
| Baseline eGFR (mL/min/1.73 m2) | 74.80 (75.62) | 148.15 (91.28) | 0.008 |
| Baseline BUN (mg/dL) | 48.13 (28.53) | 27.82 (16.88) | 0.032 |
| Chronic kidney disease | 3 (25.00) | 24 (17.00) | 0.445 |
| Accumulated dose (mg) | 4783.33 (1810.81) | 2970.68 (3112.52) | 0.049 |
| Daily dose (mg) | 279.81 (113.32) | 237.38 (91.42) | 0.132 |
| Daily dose per ABW (mg/kg/d) | 4.54 (2.41) | 3.98 (1.68) | 0.285 |
| Daily dose per IBW (mg/kg/d) | 4.87 (2.49) | 4.13 (1.79) | 0.183 |
| APACHE2 scoreb | 26.29 (6.92) | 24.36 (8.28) | 0.550 |
Data present mean (SD) for continuous data and number of subjects (proportion) for categorical data. Categorical data are chronic kidney disease
ap-value was calculated by independent t-test for continuous data and Fisher's exact test for categorical data using SPSS ver.23 (IBM corporation, Armonk, New York, U.S.)
bOnly ICU patients were calculated APACHE2 score. The number of ICU patients with AKI was 7, and the number of ICU patients with non-AKI was 90.